Context: Angiopoietin-like 8 (ANGPTL8) has been identified as a key regulator of lipid metabolism.
A ngiopoietin-like protein 8 (ANGPTL8, a.k.a. c19orf80, TD26, lipasin, RIFL, or betatrophin) is a member in the ANGPTL protein family structurally related to angiopoietins (1) . ANGPTL8 is a key regulator of triglyceride (TG) metabolism, being abundantly expressed in liver and both white and brown adipose tissue (AT) (2) (3) (4) . The expression of ANGPTL8 is stimulated by insulin and calorie intake (2, 5) . The protein regulates TG trafficking by inhibiting lipoprotein lipase in plasma, and Angptl8 2/2 mice show reduced serum TG levels (2) . Indeed, the function of ANGPTL8 mostly depends on nutritional stimuli: The suggested model is that upon feeding, this protein inhibits lipoprotein lipase after association with ANGPTL3 in heart and skeletal muscle, allowing lipolysis and fatty acid (FA) uptake into AT for the subsequent storage. Upon fasting, suppression of ANGPTL8 allows lipolysis and FA oxidation in muscle, whereas it reduces FA storage in AT (6) . Consistently, the Angptl8
mice show reduced fat gain (7), and small interfering RNA (siRNA)-mediated knockdown of Angptl8 led to reduced TG accumulation in 3T3-L1 adipocytes (3) . On the other hand, plasma ANGPTL8 is emerging as a potential biomarker for obesity-related insulin resistance and gestational (8) (9) (10) or type 1 (11, 12) and type 2 diabetes (T2D) (13) (14) (15) (16) (17) . Previously, we have shown that plasma ANGPTL8 is slightly decreased upon insulin infusion in human subjects even though its expression is positively regulated by insulin in cultured hepatocytes and adipocytes (5) . Of note, we also identified ANGPTL8 as the most insulin-sensitive gene in subcutaneous AT (SAT) of subjects undergoing euglycemic hyperinsulinemia (5, 18) . Interestingly, ANGPTL8 in liver and AT was recently demonstrated to be suppressed upon fasting by glucocorticoid signaling, and induced upon refeeding by liver X receptora (19) . However, the specific regulation and functions of ANGPTL8 in adipocytes are yet to be uncovered.
MicroRNAs (miRNAs) are small noncoding RNA molecules controlling a multitude of biological processes via translational repression or destabilization of messenger RNAs (mRNAs) (20, 21) . MiRNAs have recently emerged as key regulators of metabolic processes, being closely associated with the etiology of metabolic diseases (22) . This study aims at understanding the relationship of AT and adipocyte ANGPTL8 expression with hallmark insulin-sensitive genes ADIPOQ and SLC2A4/GLUT4 (23, 24) , inflammation, and miRNAs associated with obesity and T2D.
Material and methods

Subject recruitment
Cohort 1
Abdominal SAT samples were withdrawn from 69 women [body mass index (BMI) = 39.6 6 10.9 kg/m 2 , age = 49 6
12 years (mean 6 standard deviation), Supplemental Table 1 ] recruited at the Department of Diabetes, Endocrinology, and Nutrition and the Department of Surgery of the Hospital "Dr.
Josep Trueta" of Girona (Girona, Spain) and during elective surgical procedures (cholecystectomy and surgery of abdominal hernia) in the Hospital "Dr. Josep Trueta" of Girona. In addition, SAT biopsies withdrawn from 22 morbidly obese women before ("baseline-longitudinal" or "prebariatric-surgery") and ;2 years after surgery-induced weight loss were analyzed (Roux-en-Y gastric bypass; Table 1 ). Gene and miRNA expression measures [quantitative reverse transcription polymerase chain reaction (qRT-PCR)] were performed on all AT samples as previously explained (25) . Subjects provided written informed consent, were of Caucasian origin, and reported that their body weight was stable for at least 3 months before entering the study. No systemic diseases other than obesity and/or T2D were reported. All participants were free of any infections in the previous month before entering the study. Liver and thyroid dysfunction were specifically excluded by biochemical workup. Other exclusion criteria included (1) age above 65 or below 25 years; (2) clinically confirmed hepatic, neurologic, or other major systemic disease, including malignancy; (3) history of drug or alcohol abuse, or serum transaminase activity more than twice the upper limit of normal; (4) an elevated serum creatinine concentration; (5) acute major cardiovascular event in the previous 6 months; (6) acute illnesses and current evidence of high grade chronic inflammatory or infective diseases; and (7) mental illness rendering the subjects unable to understand the nature, scope, and possible consequences of this study. The study protocol was approved by the Ethics Committee and the Committee for Clinical Investigation of the Hospital "Dr. Josep Trueta" of Girona.
Cohort 2
For analysis of visceral AT (VAT), we recruited 19 women undergoing elective gynecological surgery for nonmalignant reasons in the Department of Obstetrics and Gynecology, Helsinki University Hospital. This study was approved by the Ethics Committee of Helsinki University Hospital, and all patients gave written informed consent. Reasons for surgery included uterine myomas accompanied with menorrhagia and/or pain, benign ovarian cysts, infertility, dysmenorrhea or rectocele. Characteristics of the subjects are summarized in Supplemental Table 2 .
Cell culture
The human monocyte cell line THP-1 (ATCC) was cultured in RPMI 1640 medium containing 10% fetal bovine serum, 5 mM glucose, 2 mM glutamine, 50 mg/mL gentamycin, and 20 mM HEPES, pH 7.4, at 37°C in a humidified 5% CO 2 air atmosphere as previously described (26) . Type 1 macrophagelike state (M1) was induced by a 24-hour treatment with 0.162 mM phorbol 12-myristate 13-acetate (Sigma Chemical Co., St. Louis, MO). Differentiated plastic-adherent cells were washed with cold Dulbecco's phosphate-buffered saline and incubated with fresh medium without phorbol 12-myristate 13-acetate. Then, differentiated M1 macrophages were treated with fresh medium containing 10 ng/mL lipopolysaccharide (LPS, Sigma Chemical Co.) for 24 hours. The lipopolysaccharide (LPS)-stimulated macrophage-conditioned media (MCM) was collected and centrifuged at 400 3 g for 5 minutes, diluted with adipocyte medium (Zen-Bio, Inc., Research Triangle Park, NC), and used to induce inflammation in mature human adipocytes as previously described (26) .
Human subcutaneous preadipocytes from a nondiabetic Caucasian male with BMI ,30 and age ,40 (Zen-Bio, Inc.) were cultured with the preadipocytes medium (Zen-Bio, Inc.) in a humidified 37°C incubator with 5% CO 2 . Cells were checked for complete confluence and differentiated using differentiation medium (Zen-Bio, Inc.) 24 hours after plating, following manufacturer's instructions. Two weeks after the initiation of differentiation, cells appeared rounded with large lipid droplets apparent in the cytoplasm. Cells were then considered isolated mature adipocytes and were incubated with fresh adipocytes medium (control) or fresh medium containing 2.5% MCM. In all treatments, fresh RPMI medium was diluted with adipocytes media to achieve identical conditions. After 48 hours of treatment, the cells were harvested and stored at -80°C for future analysis. Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes were cultured as specified previously (27) , and the HuH7 cell line in Dulbecco's modified Eagle medium, 10% fetal bovine serum, penicillin 100 IU/mL, and streptomycin (100 mg/mL).
RNA extraction
Total RNA was extracted and purified from AT and cultured cells using miRNeasy® mini kit (QIAGEN, Gaithersburg, MD). Cells and AT samples (;150 mg) were homogenized in 0.6 mL of QIAzol® Lysis Reagent (QIAGEN), a monophasic solution of phenol and guanidine thiocyanate that facilitates sample disaggregation and inhibits RNases. After addition of chloroform (0.4 volumes), the homogenate was separated into aqueous and organic phases by centrifugation (15 minutes at 12,000 3 g and 4°C). Then, the upper aqueous RNA-rich phase was isolated and absolute ethanol (1.5 volumes) was added to provide appropriate binding conditions for all RNA molecules, including miRNAs. The sample was applied to the RNeasy® mini spin column (QIAGEN) and RNA was eluted in 30 mL of RNAse-free water. Final RNA concentrations were assessed with a Nanodrop ND-1000 Spectrophotometer (Thermo Fischer Scientific, Wilmington, DE). The integrity was checked with the Nano laboratory-on-a-chip assay for total eukaryotic RNA using Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).
Gene expression analyses
For mRNA analysis, 3 mg of total RNA were reverse transcribed using the high-capacity complementary DNA archive kit (Applied Biosystems, Darmstadt, Germany) according to the manufacturer's protocol. For cohort 2, reverse transcription was carried out by using the SuperScript ® VILO TM complementary DNA synthesis kit (Invitrogen, Carlsbad, CA). MiRNAs were reverse transcribed by TaqMan® miRNA reverse transcription kit (Applied Biosystems), which provides the necessary components for optimal performance of TaqMan® microRNA assays by real-time polymerase chain reaction (PCR). Gene and miRNA expression was assessed by real time PCR using the LightCycler® 480 Real-Time PCR System (Roche Diagnostics, Barcelona, Spain), and TaqMan® technology suitable for relative gene expression quantification. The commercially available and prevalidated TaqMan® primer/ probe sets used were as follows: ribosomal protein lateral stalk subunit P0 (RPLP0, Hs99999902_m1) and RNU44 (assay# 001094) were used as endogenous controls for gene and miRNA expressions, respectively, and the chromosome 19 open reading frame 80 (C19orf80, Hs00218820_m1, or c The values represent mean 6 standard deviation.
d Of the subjects, 15 were nonmedicated, 6 were on metformin and 1 on metformin plus insulin therapy at the baseline; The medication was removed from 6 of these subjects after weight loss.
angiopoietin-like protein 8, ANGPTL8), adiponectin, C1Q and collagen domain containing (ADIPOQ, Hs00605917_m1), solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT4, Hs00168966_m1), tumor necrosis factor (Hs01113624_g1), and interleukin 6 (Hs00985639_m1) were the target genes, whereas miR-221-3p (assay number 000524), miR-107 (assay number 000443), and miR-143-3p (assay number 002249) were the target miRNAs. The reaction was performed following manufacturers' instructions in a final volume of 7mL. The cycle program consisted of an initial denaturing of 10 minutes at 95°C then 45 cycles of a 15-second denaturizing phase at 92°C and a 1-minute annealing and extension phase at 60°C. PLA2G7, DGAT1, and fatty acyl synthase (FASN) mRNAs were quantified with the SYBR Green method by using gene-specific primers (Supplemental Table 3 
Determination of plasma ANGPTL8 protein level
The concentration of ANGPTL8 in heparin plasma was determined by using a commercial enzyme-linked immunosorbent assay (Aviscera Bioscience, Santa Clara, CA).
Prediction of miRNAs targeting ANGPTL8
Putative miRNA binding sites in the 3 0 UTR of ANGPTL8 mRNA (NM_018687.6) were identified by using Targetscan Release 6.2 (www.targetscan.org/vert_61/, Whitehead Institute for Biomedical Research, Cambridge, MA).
DNA constructs
The ANGPTL8 3 0 UTR was amplified by PCR and inserted downstream of firefly luciferase (Luc) in the dual Luc vector pEZX-MT06 (GeneCopoeia, Rockville, MD). Mutagenesis to eliminate the predicted miR-221-3p binding site was carried out by using the QuikChange XL kit (Agilent, Santa Clara, CA).
Luc assays
HuH7 cells grown in 12-well plates were transfected for 24 hours with the Luc-ANGPTL8 3 0 UTR constructs together with miR-221-3p mimics (100 nM) or a nontargeting control siRNA (100 nM) by using Lipofectamine 2000 TM (Invitrogen, Carlsbad, CA). Cell lysates were subjected to measurements of firefly and Renilla Luc activities by using the dual Luc kit (Promega, Madison, WI). The firefly signals were normalized by using the Renilla signals.
Transfection and western blot analysis of SGBS cells
SGBS preadipocytes in six-well plates were transfected with miRNA mimics or a nontargeting control siRNA (aforementioned) for 24 hours by using the RNAiMax TM reagent (Thermo Fisher Scientific, Waltham, MA). After this, adipocyte differentiation was induced according to Fischer-Posovszky et al. (27) , without removing the transfection complexes, and the cells were harvested for western analysis after 4 days. Equal amounts of total protein were loaded on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. After separation, proteins were transferred onto Nitrocellulose (BioRad, Hercules, CA). The blots were detected by rabbit anti-ANGPTL8 generated by ProteoGenix (Schiltigheim, France) against peptide sequence HVQRQRREMVAQQHRLR corresponding to C-terminal amino acids 169 to 185 of ANGPTL8, and anti-b-actin (Sigma-Aldrich) for normalization, visualized by enhanced chemiluminescence (Thermo Scientific) and signals were quantified by using the ImageJ software version 1.45S (National Institutes of Health, Bethesda, MD).
TG analysis of cultured adipocytes
SGBS adipocytes were transfected for 72 hours with miR-221-3p or nontargeting siRNA (200 nM) and subjected to TG analysis using the GPO-PAP TG assay kit (Cobas, Roche/ Hitachi, Tokyo, Japan). The data were normalized to the total protein content.
Statistical analyses
Differences between groups of specimens in the experiments with cultured adipocytes were evaluated with Student's t test. The statistical association of gene and miRNA expression was assessed using Prism 7 (GraphPad Software, Inc., La Jolla, CA) software and nonparametric Spearman test. Gene expression difference analyses between groups of human subjects were done using Mann-Whitney test (Prism 7). Descriptive results of continuous variables are expressed as mean 6 standard deviation; P values , 0.05 were considered statistically significant.
Results
ANGPTL8 expression correlates with insulin-sensitive and lipogenic genes in human AT depots
Because our previous study suggested that ANGPTL8 expression is subject to a robust regulation by insulin in human AT (5, 18) , it was of interest to analyze how AT ANGPTL8 mRNA correlates with well-known markers of insulin sensitivity such as GLUT4/SLC2A4 and ADIPOQ. ANGPTL8 showed a highly significant and positive correlation with GLUT4 (r = 0.48 and P , 0.0001) in SAT of the 69 female subjects in cohort 1 (Fig. 1A) , and in VAT (r = 0.63, P = 0.004) of the subjects in cohort 2 (Fig. 1C) . In agreement, ANGPTL8 correlated significantly with ADIPOQ in subcutaneous (r =0.43, P = 0.0003) and visceral (r =0.49, P = 0.03) depots (Fig. 1B and  1D ). Significant correlations were also evident when BMI .30, and fewer than 30 subgroups of cohort 1 were analyzed separately (data not shown). Moreover, consistent with a previously demonstrated role of ANGPTL8 in white adipocyte lipid storage (2, 7, 28) , the ANGPTL8 mRNA correlated positively and highly significantly with the key lipogenic mRNAs DGAT1 and FASN (Supplemental Fig. 1A and 1B) .
Inflammation downregulates ANGPTL8 expression in human adipocytes
The expression of insulin-sensitive genes is known to be affected by inflammation and is often associated with insulin-resistant phenotypes (23, 24) . Hence, it was of interest to study whether proinflammatory stimuli impact the expression of ANGPTL8 in adipocytes. Therefore, we mimicked physiological macrophage-derived AT inflammation via incubating primary human adipocytes with 2.5% conditioned medium of LPS-stimulated THP-1 macrophages (MCM) or the corresponding control medium, followed by qRT-PCR analysis of ANGPTL8 mRNA levels. ANGPTL8 expression was markedly decreased (-86%, P , 0.001) upon treatment with 2.5% MCM (Fig. 2A) . The status of the adipocytes was validated by analyzing the expression of well-established insulin-sensitive genes suppressed by inflammation, Adiponectin (-51%, P , 0.01) and GLUT4 (-61%, P , 0.001), the mRNAs of that markedly decreased upon the 2.5% MCM incubation ( Fig. 2A) , and mRNAs for the inflammatory mediators tumor necrosis factor-a and interleukin 6, which increased three-and 13-fold (P , 0.001 and P , 0.01), respectively (Fig. 2B) . The inflammation-mimicking treatment strongly suppressed mRNAs encoding the key lipogenic genes, DGAT1 and FASN ( Fig. 2A) .
Inflammation increases the expression of miR-221-3p in adipocytes
Because it is fully recognized that inflammation modifies the expression of a number of genes through miRNA regulation (29-32), we considered altered miRNA expression at the forefront of potential mechanisms by which adipocyte ANGPTL8 could be suppressed under inflammatory conditions. Therefore, we analyzed the 3 0 UTR of ANGPTL8 mRNA for tentative miRNA binding sites. Interestingly, the short 280-nt 3 0 UTR sequence of ANGPTL8 contained predicted binding sites for several miRNAs that have been previously associated with obesity, insulin resistance or T2D: miR-107, miR-143-3p, and miR-221-3p (Fig. 2C) . The expression of these miRNAs in primary adipocytes was analyzed under inflammatory conditions similar to the ANGPTL8 gene expression (aforementioned). In agreement with previous results, miR-221-3p, but not miR-107 or miR-143-3p, was significantly (2.5-fold, P , 0.001) upregulated after incubation of adipocytes with 2.5% MCM medium (Fig. 2D) . https://academic.oup.com/jcemmiR-221-3p binds to the 3 0 UTR of ANGPTL8 mRNA To study whether ANGPTL8 is a direct target of miR-221-3p, ANGPTL8 3 0 UTR Luc reporter constructs were transfected to HuH7 cells along with miR-221-3p mimics or a nontargeting control siRNA, followed by recording of the luminescence with a dual Luc assay. A significant 28.5% (P , 0.001) reduction of the Luc signal was observed in miR-221-3p-transfected cells as compared with nontargeting controls (Fig. 3A) . Of note, the Luc activity was not affected in cells transfected with miR-221-3p and a mutated ANGPTL8 3 0 UTR reporter construct with the miR-221-3p binding site destroyed (Fig. 3B) , demonstrating that miR-221-3p specifically targets the 3 0 UTR of ANGPTL8.
miR-221-3p suppresses ANGPTL8 expression in adipocytes
To further validate the regulation of ANGPTL8 expression by miR-221-3p in adipocytes, SGBS preadipocytes were transfected with miR-221-3p mimics or a nontargeting control siRNA, and the expression of ANGPTL8 protein was analyzed by western blotting after 4 days of adipocyte differentiation. Expression of ANGPTL8 protein was reduced by 46% in the miR-221-3p-transfected cells (P , 0.01), as compared with the nontargeting control ( Fig. 3C and 3D) . Concomitantly, transfection of SGBS adipocytes with miR-221-3p mimics significantly suppressed TG storage by the cells (Supplemental Fig. 1C ).
Correlation of miR-221-3p with ANGPTL8 in AT in vivo
To analyze a putative correlation of miR-221-3p and ANGPTL8 mRNA in human white AT in vivo, we quantified these RNAs by qRT-PCR in two cohorts of human subjects. We first analyzed SAT biopsies of cohort 1, consisting of 69 female subjects (Supplemental Table 1 ). Here, a nominal trend of negative correlation between miR-221-3p and ANGPTL8 was observed (r = -0.16, P = 0.18; Fig. 4A) . A similar trend (r = -0.25, P = 0.3) was detected in VAT biopsies from cohort 2, consisting of 19 women (BMI 31.6 6 3.2) undergoing elective gynecological surgery (Supplemental Table 2 ; Fig. 4B ). Analysis of the obese (BMI .30, N = 48) subgroup of cohort 1 revealed a similar negative correlation trend (r = -0.19, P = 0.18; Fig. 4C ), which was completely absent in the normal or moderately overweight subgroup (BMI ,30, N = 21, r = -0.03; Fig. 4D ). We next analyzed the mRNA and miRNA quantities in a subgroup of cohort 1 consisting of 22 morbidly obese subjects who underwent bariatric surgery. SAT biopsies of these subjects were withdrawn before the operation and after a ;2-year period of postoperation weight loss (Table 1) . After the operation and the resulting significant weight loss (BMI from 43.4 6 5.0 to 29.2 6 5.7, P , 0.0001), AT GLUT4/SLC2A4 expression as a marker insulin sensitivity, and serum lipid (high-density lipoprotein and TG) values were markedly improved. Moreover, the AT expression of miR-221-3p was diminished and the ANGPTL8 mRNA showed an increasing, yet statistically insignificant trend (Table 1) . Interestingly, a significant negative correlation (r = -0.51, P = 0.016) between miR-221-3p and ANGPTL8 was observed in the preoperation biopsies (Fig. 4E) , but was absent in the post-weight loss AT specimens (Fig. 4F) . When the bariatric surgery cohort was stratified into subjects with (n = 7) or without (n = 15) metformin or metformin plus insulin therapy, we found that the negative correlation of ANGPTL8 and miR-221-3p originated from the nonmedicated subgroup, and was thus strengthened (r = -0.70, P = 0.003) by exclusion of the seven medicated subjects. These findings suggest that weight loss and metabolic improvement after bariatric surgery in morbidly obese patients may induce a shift in the mechanisms controlling AT ANGPTL8 expression, and that diabetes medication may modify this regulation.
Lack of correlation between SAT ANGPTL8 mRNA and circulating ANGPTL8 protein
Several studies have documented increased plasma ANGPTL8 in subjects with obesity-related insulin resistance or various forms of diabetes (see Introduction). We therefore determined the concentration of ANGPTL8 protein in heparin plasma available from 16 subjects of the bariatric surgery group. No correlation was detectable between the SAT ANGPTL8 mRNA and the plasma ANGPTL8 concentration at baseline (r = -0.13, P = 0.96) or after weight loss (r = 0.020, P = 0.93). Of note, the plasma ANGPTL8 concentration increased significantly after the weight loss (baseline 105.6 619.9 ng/ml, after weight loss 119.8 6 17.6 ng/mL; P = 0.049).
ANGPTL8 and miR-221-3p correlate with an adipose inflammatory gene in vivo Phosholipase A2 G7 (PLA2G7) was identified as the single most upregulated SAT inflammatory gene in obese, insulin-resistant subjects in the genome-wide transcriptomic study of Soronen et al. (18) , and has also been found upregulated in inflamed AT in other investigations (33) (34) (35) . We therefore analyzed the quantity of this mRNA in the SAT biopsies of the bariatric surgery subgroup of cohort 1, and its potential correlations with ANGPTL8 and miR-221-3p. Importantly, PLA2G7 displayed significant negative (r = -0.50, P = 0.01) and positive (r = 0.57, P = 0.006) correlations with ANGPTL8 and miR-221-3p, respectively ( Fig. 5A and 5B). These observations are consistent with the hypothesis that white AT inflammation is an important determinant of ANGPTL8 expression, regulated by miR-221-3p. Of note, when categorized based on PLA2G7 expression in this cohort, there was a significant difference in ANGPTL8 (P = 0.009) and a borderline significance trend in miR-221-3p (P = 0.06) between the PLA2G7 low-and high-expression groups as divided at the median (Fig. 5C) .
Discussion
In the current study, we show that ANGPTL8 expression in human SAT and VAT shows a strong positive correlation with hallmark insulin-regulated or adipogenic genes such as GLUT4/SLC2A4 and ADIPOQ, DGAT1, and FASN and that all these mRNAs are suppressed by incubation of mature adipocytes with M1-type macrophage conditioned medium mimicking AT inflammation. Among the miRNAs shown to be dysregulated in obesity, insulin resistance or T2D, and predicted to target the 3 0 UTR of ANGPTL8, miR-221-3p was found to be strongly induced in adipocytes under the inflammatory conditions with simultaneous suppression of ANGPTL8. MiR-221-3p was demonstrated to directly regulate the expression of ANGPTL8 and to show a significant negative correlation with this mRNA in SAT biopsies of morbidly obese patients before bariatric surgery, and this correlation disappears after weight loss. Consistent with the notion that AT inflammation modifies ANGPTL8 expression, possibly via miR-221-3p, the AT inflammatory marker PLA2G7 correlated negatively with ANGPTL8 and positively with miR-221-3p in morbidly obese human subjects.
ANGPTL8 was previously identified as the most insulin-sensitive individual gene in SAT of human subjects undergoing euglycemic hyperinsulinemia (5, 18) . It was therefore of interest to study whether ANGPTL8 expression correlates with other insulin-regulated genes and whether its expression is suppressed by inflammation as shown for a number of insulin-sensitive genes (23, 24) . We found that AT ANGPTL8 expression directly correlates with the expression of the established insulinregulated genes GLUT4/SLC2A4 and ADIPOQ, implying that ANGPTL8 expression level in adipocytes reflects their insulin sensitivity. Moreover, consistent with a previously demonstrated role of ANGPTL8 in promoting white adipocyte lipid storage (2, 7, 28) , the ANGPTL8 mRNA correlated positively and highly significantly with the key lipogenic mRNAs DGAT1 and FASN. Several studies suggest that serum ANGPTL8 protein levels are elevated and not reduced in insulinresistant and subjects with T2D (9, 11, 13, 15, 17) . However, the data of Gomez-Ambrosi et al. suggested that serum ANGPTL8 levels are reduced in patients with T2D and dyslipidemia (17, 36) . Moreover, the study of Pascual-Corrales et al. (37) suggested that circulating ANGPTL8 increased after surgically induced but not after diet-induced weight loss. The former observation is consistent with plasma ANGPTL8 analysis in our bariatric surgery cohort. However, we found no correlation of the AT ANGPTL8 mRNA and the circulating protein levels. The present results suggest that adipocyte ANGPTL8 expression is suppressed rather than enhanced in the inflamed AT of morbidly obese subjects. The controversies concerning the regulation of circulating ANGPTL8 underscore the fact that the mechanisms determining serum ANGPTL8 levels are poorly understood and that further study to elucidate its tissue sources, the regulation of its secretion, and the processes controlling its turnover is necessary. We find it likely that the liver, which also expresses ANGPTL3, the functional partner of ANGPTL8 (1, 4) , is a major source of circulating ANGPTL8.
The expression of ANGPTL8 in adipocytes was found to be strongly suppressed under inflammatory conditions, similar to GLUT4/SLC2A4, ADIPOQ, DGAT1, and FASN. Moreover, analysis of prebariatric-surgery subjects revealed a significant negative correlation of the AT inflammatory marker PLA2G7 (18, (33) (34) (35) with ANGPTL8 gene expression. Because inflammation is known to contribute to adipocyte insulin resistance (38) (39) (40) , we envision that the suppression of ANGPTL8 under these conditions may be at the forefront of the dysregulation of adipocyte lipid metabolism, possibly even contributing to the insulin resistance of adipocytes associated with AT inflammation. Because several miRNAs are known to be elevated in AT upon inflammation in obese and/or diabetic subjects (41) (42) (43) , one of the possible mechanisms by which inflammation may reduce adipocyte ANGPTL8 expression is through miRNAs. Therefore, we analyzed the 3 0 UTR of ANGPTL8 mRNA and identified potential binding sites for three The expression of ANGPTL8 and miR-221-3p in PLA2G7 low (black bars) and high (gray bars) expression groups (prebariatric-surgery subjects). The data represents mean 6 standard error of the mean. **P , 0.01; ***P , 0.001. miRNAs: miR-107, miR-143-3p, and miR-221-3p. These miRNAs have been reported to be involved in the insulin resistance of AT (44) (45) (46) . Among them, miR-221-3p was markedly increased under the conditions used to induce inflammatory stimulation in primary human adipocytes and correlated positively with the inflammatory marker PLA2G7 in the prebariatric-surgery subjects. Thus, further experiments were focused on miR-221-3p.
Luc reporter assays using Luc-ANGPTL8 3 0 UTR constructs and miR-221-3p mimics demonstrated that miR-221-3p directly targets the ANGPTL8 3 0 UTR. Further validation experiments showed that miR-221-3p reduces endogenous ANGPTL8 protein expression and, consistently, the TG storage in SGBS adipocytes. Earlier studies have demonstrated that miR-221 also suppresses adiponectin receptor-1 expression and interferes with adiponectin signaling and insulin sensitivity of adipocytes (45) . MiR-222, another member of the miR-221/222 family, reduces GLUT4 expression and may interfere with insulin sensitivity in gestational diabetes (47) . This indicates that the miR-221/222 family may play an important role in controlling adipocyte insulin sensitivity and metabolism (48, 49) . A negative correlation between miR-221-3p and ANGPTL8 was observed in the SAT of a morbidly obese subset of human cohort 1 before bariatric surgery, but vanished after the surgery-induced weight loss concomitantly with improvement of dyslipidemia and markers of insulin sensitivity and a decrease of miR-221-3p. Of note, this negative correlation seemed to derive mainly from the nonmedicated subjects within the cohort. These observations lend further support to the notion that miR-221-3p is a physiologically relevant regulator of ANGPTL8 under specific physiological settings such as severe obesity with inflammation. The present human cohorts consisted of females only. The report of Wu et al. (50) suggested that the circulating ANGPTL8 concentration may differ between genders. Therefore, even though we do not believe that AT is a major source of circulating ANGPTL8, the possibility of a differential regulation of AT ANGPTL8 expression in males and females under inflammatory conditions warrants study in the future. Loss of correlation upon weight loss, coinciding with improvement of AT metabolic and inflammatory status, suggests that under these conditions other mechanisms independent of miR-221 begin to dominate in the control of ANGPTL8 expression. Because, besides destabilization of messages, suppression of mRNA translation is a key mode of miRNA action (20) , a better correlation of miR-221 with AT ANGPTL8 might be detectable at the protein level.
In conclusion, the current study shows that the expression of the key regulator of lipid metabolism, ANGPTL8, in human AT correlates with hallmark insulin-sensitive and lipogenic genes, and is suppressed by inflammatory signals. ANGPTL8 is targeted by miR-221-3p, a miRNA that has been associated with metabolic disease and is induced upon inflammatory stimulation of adipocytes. ANGPTL8 correlates negatively with this miRNA and the adipose inflammatory gene PLA2G7 in the SAT of morbidly obese subjects elected for bariatric surgery. The findings provide clues of ANGPTL8 function in adipocytes and its dysregulation in metabolic disease.
